| Philip C Bird, MD | |
|
1125 N Porter Ave, Norman, OK 73071-6443 | |
| (405) 360-2777 | |
| (405) 360-2780 |
| Full Name | Philip C Bird |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 53 Years |
| Location | 1125 N Porter Ave, Norman, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033187208 | NPI | - | NPPES |
| 100134120A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 9875 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norman Regional | Norman, OK | Hospital |
| Grady Memorial Hospital | Chickasha, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Norman Regional Providers Specialty Care | 5496900706 | 138 |
News Archive
Roche announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.
Every state can now lay claim to the nanotechnology revolution. Data released today by the Project on Emerging Nanotechnologies (PEN) highlights more than 1,200 companies, universities, government laboratories, and other organizations across all 50 U.S. states and in the District of Columbia that are involved in nanotechnology research, development, and commercialization. This number is up 50 percent from the 800 organizations identified just two years ago.
Judith Smith, now 71, was at a routine appointment several years ago with her longtime ophthalmologist when the doctor made a comment that her right eye looked a little suspicious for glaucoma, an incurable disease that occurs when the optic nerve is damaged by pressure building inside the eye.
Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.
It is well known that in addition to urethral catheter associated discomfort, there is an increased risk of ascending urethral infection, inflammation and stricture formation with urethral catheters.
› Verified 5 days ago
| Entity Name | Norman Regional Providers Specialty Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548513773 PECOS PAC ID: 5496900706 Enrollment ID: O20130312000200 |
News Archive
Roche announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.
Every state can now lay claim to the nanotechnology revolution. Data released today by the Project on Emerging Nanotechnologies (PEN) highlights more than 1,200 companies, universities, government laboratories, and other organizations across all 50 U.S. states and in the District of Columbia that are involved in nanotechnology research, development, and commercialization. This number is up 50 percent from the 800 organizations identified just two years ago.
Judith Smith, now 71, was at a routine appointment several years ago with her longtime ophthalmologist when the doctor made a comment that her right eye looked a little suspicious for glaucoma, an incurable disease that occurs when the optic nerve is damaged by pressure building inside the eye.
Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.
It is well known that in addition to urethral catheter associated discomfort, there is an increased risk of ascending urethral infection, inflammation and stricture formation with urethral catheters.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Philip C Bird, MD 1125 N Porter Ave, Norman, OK 73071-6443 Ph: (405) 360-2777 | Philip C Bird, MD 1125 N Porter Ave, Norman, OK 73071-6443 Ph: (405) 360-2777 |
News Archive
Roche announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.
Every state can now lay claim to the nanotechnology revolution. Data released today by the Project on Emerging Nanotechnologies (PEN) highlights more than 1,200 companies, universities, government laboratories, and other organizations across all 50 U.S. states and in the District of Columbia that are involved in nanotechnology research, development, and commercialization. This number is up 50 percent from the 800 organizations identified just two years ago.
Judith Smith, now 71, was at a routine appointment several years ago with her longtime ophthalmologist when the doctor made a comment that her right eye looked a little suspicious for glaucoma, an incurable disease that occurs when the optic nerve is damaged by pressure building inside the eye.
Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.
It is well known that in addition to urethral catheter associated discomfort, there is an increased risk of ascending urethral infection, inflammation and stricture formation with urethral catheters.
› Verified 5 days ago
Justin Elliot Fields, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 950 N Porter, Suite 300, Norman, OK 73071 Phone: 405-329-0121 Fax: 405-292-6099 | |
Sunil Thomas Mathew, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3500 Healthplex Pkwy Ste 200, Norman, OK 73072 Phone: 405-515-2222 Fax: 405-515-2208 | |
Aaron Lee Boyd, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 650 24th Ave Sw, Suite 110, Norman, OK 73069 Phone: 405-307-5337 Fax: 405-253-4148 | |
Archana Gautam, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3500 Healthplex Pkwy, Suite 200, Norman, OK 73072 Phone: 405-515-2222 Fax: 405-307-5617 | |
Robert Michael Holbrook, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1515 N Porter Ave, Suite 200, Norman, OK 73071 Phone: 405-366-8619 Fax: 405-366-1839 | |
Katherine Hays, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3500 Healthplex Pkwy Ste 200, Norman, OK 73072 Phone: 405-515-2222 Fax: 405-307-5618 |